结直肠高危腺瘤与血清胆红素相关性研究
Association between Advanced Colorectal Adenoma and Serum Bilirubin
DOI: 10.12677/ACM.2023.132292, PDF,   
作者: 许子桐：青岛大学青岛医学院，山东 青岛；张海燕, 修 辉, 张 珊, 姜 娜, 王荣玉, 刘希双*：青岛大学附属医院消化内科，山东 青岛
关键词: 结直肠高危腺瘤；血清胆红素；风险因素；Advanced Colorectal Adenoma； Serum Bilirubin； Risk Factors
摘要: 目的：本研究旨在分析结直肠高危腺瘤的风险因素，以及与血清胆红素水平的关系。方法：本研究纳入2017年5月至2022年6月在青岛大学附属医院接受结肠镜检查的415例患者。采用单因素分析研究结直肠高危腺瘤风险因素，多因素logistic回归进一步分析结直肠高危腺瘤与血清胆红素的关系。结果：高危腺瘤组中男性、结直肠癌家族史患者更多。与非高危腺瘤组相比，高危腺瘤组患者平均年龄、血清直接胆红素(DBIL)、中性粒细胞/淋巴细胞比值(NLR)更高，总胆固醇(TC)更低。血清直接胆红素与结直肠高危腺瘤独立相关。结论：性别、年龄、结直肠癌家族史、直接胆红素、中性粒细胞/淋巴细胞比值、总胆固醇与结直肠高危腺瘤相关。血清直接胆红素水平是结直肠高危腺瘤的独立风险因素。
Abstract: Objective: The purpose of this study was to analyze risk factors of advanced colorectal adenoma and the association between advanced colorectal adenoma and serum bilirubin. Methods: A total of 415 patients who underwent colonoscopy in the Affiliated Hospital of Qingdao University from May 2017 to June 2022 were included in this study. Univariate analysis was used to study the risk factors of advanced colorectal adenoma, and multivariate logistic regression was used to further analyze the association between advanced colorectal adenoma and serum bilirubin. Results: The advanced col-orectal adenoma group had more patients with male sex and a family history of colorectal cancer. The mean age, serum direct bilirubin (DBIL), neutrophil/lymphocyte ratio (NLR) of patients with advanced colorectal adenoma was higher than those without. Patients with advanced colorectal adenoma had lower total cholesterol (TC). Serum direct bilirubin was independently associated with advanced colorectal adenoma. Conclusions: Gender, age, a family history of colorectal cancer, serum direct bilirubin, neutrophil/lymphocyte ratio and total cholesterol are associated with ad-vanced colorectal adenoma. Serum direct bilirubin level is an independent risk factor for advanced colorectal adenoma.
文章引用：许子桐, 张海燕, 修辉, 张珊, 姜娜, 王荣玉, 刘希双. 结直肠高危腺瘤与血清胆红素相关性研究[J]. 临床医学进展, 2023, 13(2): 2093-2102. https://doi.org/10.12677/ACM.2023.132292

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Sung, J.J., Ng, S.C., Chan, F.K., et al. (2015) An Updated Asia Pacific Consensus Recommendations on Colorectal Cancer Screening. Gut, 64, 121-132. [Google Scholar] [CrossRef] [PubMed]
[3] Chen, W., Sun, K., Zheng, R., et al. (2018) Cancer Incidence and Mortality in China, 2014. Chinese Journal of Cancer Research, 30, 1-12. [Google Scholar] [CrossRef] [PubMed]
[4] Vogelstein, B., Fearon, E.R., Hamilton, S.R., et al. (1988) Genetic Alterations during Colorectal-Tumor Development. The New England Journal of Medicine, 319, 525-532. [Google Scholar] [CrossRef] 
[5] 中华医学会消化病学分会. 中国结直肠肿瘤综合预防共识意见(2021年, 上海) [J]. 中华消化杂志, 2021, 41(11): 726-759.
[6] Cao, Y., Deng, S., Yan, L., et al. (2021) A Nomogram Based on Pretreatment Levels of Serum Bilirubin and Total Bile Acid Levels Predicts Survival in Colorectal Cancer Patients. BMC Cancer, 21, 85. [Google Scholar] [CrossRef] [PubMed]
[7] Wei, T.T., Wang, L.L., Yin, J.R., et al. (2017) Relationship be-tween Red Blood Cell Distribution Width, Bilirubin, and Clinical Characteristics of Patients with Gastric Cancer. Interna-tional Journal of Laboratory Hematology, 39, 497-501. [Google Scholar] [CrossRef] [PubMed]
[8] Horsfall, L.J., Rait, G., Walters, K., et al. (2011) Serum Bilirubin and Risk of Respiratory Disease and Death. JAMA, 305, 691-697. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, X., Meng, Q.H., Ye, Y., et al. (2015) Prognostic Significance of Pretreatment Serum Levels of Albumin, LDH and Total Bilirubin in Patients with Non-Metastatic Breast Cancer. Carcinogenesis, 36, 243-248. [Google Scholar] [CrossRef] [PubMed]
[10] Sun, H., He, B., Nie, Z., et al. (2017) A Nomogram Based on Serum Bilirubin and Albumin Levels Predicts Survival in Gastric Cancer Patients. Oncotarget, 8, 41305-41318. [Google Scholar] [CrossRef] [PubMed]
[11] Li, N., Xu, M., Cai, M.-Y., et al. (2015) Elevated Serum Bilirubin Levels Are Associated with Improved Survival in Patients with Curatively Resected Non-Small-Cell Lung Cancer. Can-cer Epidemiology, 39, 763-768. [Google Scholar] [CrossRef] [PubMed]
[12] Zucker, S.D., Horn, P.S. and Sherman, K.E. (2004) Serum Bili-rubin Levels in the U.S. Population: Gender Effect and Inverse Correlation with Colorectal Cancer. Hepatology, 40, 827-835. [Google Scholar] [CrossRef] [PubMed]
[13] Zhang, Q., Ma, X., Xu, Q., et al. (2017) Nomograms In-corporated Serum Direct Bilirubin Level for Predicting Prognosis in Stages II and III Colorectal Cancer after Radical Re-section. Oncotarget, 8, 71138-71146. [Google Scholar] [CrossRef] [PubMed]
[14] Gao, C., Fang, L., Li, J.T. and Zhao, H.C. (2016) Significance and Prognostic Value of Increased Serum Direct Bilirubin Level for Lymph Node Metastasis in Chinese Rectal Cancer Pa-tients. World Journal of Gastroenterology, 22, 2576-2584. [Google Scholar] [CrossRef] [PubMed]
[15] Gumpenberger, T., Brezina, S., Keski-Rahkonen, P., et al. (2021) Untargeted Metabolomics Reveals Major Differences in the Plasma Metabolome between Colorectal Cancer and Colo-rectal Adenomas. Metabolites, 11, 119. [Google Scholar] [CrossRef] [PubMed]
[16] Yeoh, K.G., Ho, K.Y., Chiu, H.M., et al. (2011) The Asia-Pacific Colorectal Screening Score: A Validated Tool That Stratifies Risk for Colorectal Advanced Neoplasia in Asymptomatic Asian Subjects. Gut, 60, 1236-1241. [Google Scholar] [CrossRef] [PubMed]
[17] Kim, S.E., Paik, H.Y., Yoon, H., et al. (2015) Sex- and Gen-der-Specific Disparities in Colorectal Cancer Risk. World Journal of Gastroenterology, 21, 5167-5175. [Google Scholar] [CrossRef] [PubMed]
[18] Keum, N. and Giovannucci, E. (2019) Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies. Nature Reviews Gastroenterology & Hepatology, 16, 713-732. [Google Scholar] [CrossRef] [PubMed]
[19] Botteri, E., Borroni, E., Sloan, E.K., et al. (2020) Smoking and Colorectal Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis. The American Journal of Gastroenterol-ogy, 115, 1940-1949. [Google Scholar] [CrossRef] [PubMed]
[20] Figueiredo, J.C., Crockett, S.D., Snover, D.C., et al. (2015) Smoking-Associated Risks of Conventional Adenomas and Serrated Polyps in the Colorectum. Cancer Causes Control, 26, 377-386. [Google Scholar] [CrossRef] [PubMed]
[21] Soltani, G., Poursheikhani, A., Yassi, M., et al. (2019) Obesity, Diabetes and the Risk of Colorectal Adenoma and Cancer. BMC Endocrine Disorders, 19, 113. [Google Scholar] [CrossRef] [PubMed]
[22] Thanikachalam, K. and Khan, G. (2019) Colorectal Cancer and Nutrition. Nutrients, 11, 164. [Google Scholar] [CrossRef] [PubMed]
[23] Dekker, E., Tanis, P.J., Vleugels, J.L.A., et al. (2019) Colorectal Cancer. The Lancet, 394, 1467-1480. [Google Scholar] [CrossRef] 
[24] Lu, Y., Xin, D. and Wang, F. (2019) Predictive Significance of Preoperative Systemic Immune-Inflammation Index Determination in Postoperative Liver Metastasis of Colorectal Cancer. OncoTargets and Therapy, 12, 7791-7799. [Google Scholar] [CrossRef] 
[25] Kim, J.H., Cho, K.I., Kim, Y.A. and Park, S.J. (2017) Elevated Neu-trophil-to-Lymphocyte Ratio in Metabolic Syndrome Is Associated with Increased Risk of Colorectal Adenoma. Meta-bolic Syndrome and Related Disorders, 15, 393-399. [Google Scholar] [CrossRef] [PubMed]
[26] He, Q., Du, S., Wang, X., et al. (2022) Development and Validation of a Nomogram Based on Neutrophil-to-Lymphocyte Ratio and Fibrinogen-to-Lymphocyte Ratio for Predicting Recurrence of Colorectal Adenoma. Journal of Gastrointestinal Oncology, 13, 2269-2281. [Google Scholar] [CrossRef] [PubMed]
[27] Li, Y., Jia, H., Yu, W., et al. (2016) Nomograms for Predicting Prognos-tic Value of Inflammatory Biomarkers in Colorectal Cancer Patients after Radical Resection. International Journal of Cancer, 139, 220-231. [Google Scholar] [CrossRef] [PubMed]
[28] Pine, J.K., Morris, E., Hutchins, G.G., et al. (2015) Systemic Neutro-phil-to-Lymphocyte Ratio in Colorectal Cancer: the Relationship to Patient Survival, Tumour Biology and Local Lym-phocytic Response to Tumour. British Journal of Cancer, 113, 204-211. [Google Scholar] [CrossRef] [PubMed]
[29] Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Can-cer-Related Inflammation. Nature, 454, 436-444. [Google Scholar] [CrossRef] [PubMed]
[30] Condeelis, J. and Pollard, J.W. (2006) Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis. Cell, 124, 263-266. [Google Scholar] [CrossRef] [PubMed]
[31] Jiraskova, A., Novotny, J., Novotny, L., et al. (2012) Association of Serum Bilirubin and Promoter Variations in HMOX1 and UGT1A1 Genes with sporadic Colorectal Cancer. Internation-al Journal of Cancer, 131, 1549-1555. [Google Scholar] [CrossRef] [PubMed]
[32] Ioannou, G.N., Liou, I.W. and Weiss, N.S. (2006) Serum Bilirubin and Col-orectal Cancer Risk: A Population-Based Cohort Study. Alimentary Pharmacology & Therapeutics, 23, 1637-1642. [Google Scholar] [CrossRef] [PubMed]
[33] Carmel, R., Wong, E.T., Weiner, J.M. and Johnson, C.S. (1985) Racial Differences in Serum Total Bilirubin Levels in Health and in Disease (Pernicious Anemia). JAMA, 253, 3416-3418. [Google Scholar] [CrossRef] [PubMed]
[34] Yang, L., Ge, L.-Y., Yu, T., et al. (2018) The Prognostic Impact of Serum Bilirubin in Stage IV Colorectal Cancer Patients. Journal of Clinical Laboratory Analysis, 32, e22272. [Google Scholar] [CrossRef] [PubMed]
[35] Wagner, K.-H., Shiels, R.G., Lang, C.A., et al. (2018) Diagnostic Criteria and Contributors to Gilbert’s Syndrome. Critical Reviews in Clinical Laboratory Sciences, 55, 129-139. [Google Scholar] [CrossRef] [PubMed]
[36] Seyed Khoei, N., Jenab, M., Murphy, N., et al. (2020) Cir-culating Bilirubin Levels and Risk of Colorectal Cancer: Serological and Mendelian Randomization Analyses. BMC Medicine, 18, 229. [Google Scholar] [CrossRef] [PubMed]
[37] Vítek, L. and Ostrow, J.D. (2009) Bilirubin Chemistry and Me-tabolism; Harmful and Protective Aspects. Current Pharmaceutical Design, 15, 2869-2883. [Google Scholar] [CrossRef] [PubMed]
[38] Liu, X., Cheng, D., Kuang, Q., et al. (2013) Association be-tween UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in Caucasians. PLOS ONE, 8, e58489. [Google Scholar] [CrossRef] [PubMed]
[39] Muraca, M. and Fevery, J. (1984) Influence of Sex and Sex Steroids on Bilirubin Uridine Diphosphate-Glucuronosyl- transferase Activity of Rat Liver. Gastroenterology, 87, 308-313. [Google Scholar] [CrossRef] [PubMed]
[40] Bajro, M.H., Josifovski, T., Panovski, M., et al. (2012) Pro-moter Length Polymorphism in UGT1A1 and the Risk of Sporadic Colorectal Cancer. Cancer Genetics, 205, 163-167. [Google Scholar] [CrossRef] [PubMed]
[41] Rodrigues, C.M.P., Solá, S., Brito, M.A., et al. (2002) Bili-rubin Directly Disrupts Membrane Lipid Polarity and Fluidity, Protein Order, and Redox Status in Rat Mitochondria. Journal of Hepatology, 36, 335-341. [Google Scholar] [CrossRef] 
[42] Keshavan, P., Schwemberger, S.J., Smith, D.L., et al. (2004) Unconjugated Bilirubin Induces Apoptosis in Colon Cancer Cells by Triggering Mitochondrial Depolarization. Interna-tional Journal of Cancer, 112, 433-445. [Google Scholar] [CrossRef] [PubMed]
[43] Wagner, K.-H., Wallner, M., Mölzer, C., et al. (2015) Looking to the Hori-zon: The Role of Bilirubin in the Development and Prevention of Age-Related Chronic Diseases. Clinical Science (Lon-don), 129, 1-25. [Google Scholar] [CrossRef] 
[44] Sedlak, T.W., Saleh, M., Higginson, D.S., et al. (2009) Bilirubin and Glutathione Have Complementary Antioxidant and Cytoprotective Roles. Proceedings of the National Academy of Sci-ences of the United States of America, 106, 5171-5176. [Google Scholar] [CrossRef] [PubMed]
[45] Rao, P., Suzuki, R., Mizobuchi, S., et al. (2006) Bilirubin Exhibits a Novel Anti-Cancer Effect on Human Adenocarcinoma. Bio-chemical and Biophysical Research Communications, 342, 1279-1283. [Google Scholar] [CrossRef] [PubMed]
[46] Deng, C.-C., Xu, M., Li, J., et al. (2016) Unconjugated Bilirubin Is a Novel Prognostic Biomarker for Nasopharyngeal Carcinoma and Inhibits Its Metastasis via Antioxidation Activity. Cancer Prevention Research (Phila), 9, 180-188. [Google Scholar] [CrossRef] 
[47] Ahn, B. and Ohshima, H. (2001) Suppression of Intestinal Polyposis in Apc(Min/+) Mice by Inhibiting Nitric Oxide Production. Cancer Research, 61, 8357-8360.
[48] Smith, D.L., Keshavan, P., Avissar, U., et al. (2010) Sodium Taurocholate Inhibits Intestinal Adenoma Formation in APCMin/+ Mice, Potentially through activation of the Farnesoid X Receptor. Carcinogenesis, 31, 1100-1109. [Google Scholar] [CrossRef] [PubMed]
[49] Keshavan, P., Deem, T.L., Schwemberger, S.J., et al. (2005) Unconju-gated Bilirubin Inhibits VCAM-1-Mediated Transendothelial Leukocyte Migration. The Journal of Immunology, 174, 3709-3718. [Google Scholar] [CrossRef] [PubMed]
[50] Wu, T.C. (2007) The Role of Vascular Cell Adhesion Mole-cule-1 in Tumor Immune Evasion. Cancer Research, 67, 6003-6006. [Google Scholar] [CrossRef] 

为你推荐